Table 4 Associations of rituximab use,... | American Society of Hematology

Table 4

Associations of rituximab use, type of initial chemotherapeutic regimen, and baseline CD4 count with cause of death (polytomous model)

Factors	Death from all causes	Cause of death (OR; 95% CI; P)
Factors	Death from all causes	TRM (n = 180)	PD (n = 457)	HIV (n = 57)	Other (n = 91)
Non-rituximab use (n = 898)	595	Reference	Reference	Reference	Reference
Rituximab use (n = 537)	190	0.68 (0.44-1.06; .09)	0.30 (0.21-0.41; <.001)	0.58 (0.30-1.12; .11)	0.38 (0.20-0.69; .002)
Chemotherapy regimen
CHOP (n = 614)	321	Reference	Reference	Reference	Reference
Infusional regimens (EPOCH, n = 145; CDE, n = 184)	41	0.28 (0.14-0.57; <.001)	1.54 (1.12-2.11; .008)	0.64 (0.28-1.49; .30)	1.53 (0.83-2.83; .18)
Dose-intense regimens (n = 312)*	162	1.24 (0.82-1.88; .30)	0.90 (0.66-1.22; .49)	1.85 (0.87-3.93; .11)	0.76 (0.35-1.62; .47)
Less dose-intense regimens (n = 180)†	153	1.26 (0.77-2.06; .37)	1.75 (1.29-2.37; <.001)	0.14 (0.02-1.07; .06)	0.56 (0.22-1.41; .22)
Baseline CD4 count (cells/µL)‡
<50 (n = 175)	124	0.96 (0.80-1.16; .68)	1.04 (0.91-1.19; .53)	0.74 (0.57-0.97; .03)	0.96 (0.76-1.22; .75)
50-199 (n = 373)	217	0.97 (0.93-1.00; .08)	0.99 (0.96-1.02; .42)	1.00 (0.93-1.08; .93)	0.96 (0.91-1.01; .13)
≥200 (n = 829)	413	1.00 (1.00-1.00; .97)	1.00 (1.00-1.00; .68)	0.96 (0.92-0.99; .02)	1.00 (0.99-1.00; .14)

Factors	Death from all causes	Cause of death (OR; 95% CI; P)
Factors	Death from all causes	TRM (n = 180)	PD (n = 457)	HIV (n = 57)	Other (n = 91)
Non-rituximab use (n = 898)	595	Reference	Reference	Reference	Reference
Rituximab use (n = 537)	190	0.68 (0.44-1.06; .09)	0.30 (0.21-0.41; <.001)	0.58 (0.30-1.12; .11)	0.38 (0.20-0.69; .002)
Chemotherapy regimen
CHOP (n = 614)	321	Reference	Reference	Reference	Reference
Infusional regimens (EPOCH, n = 145; CDE, n = 184)	41	0.28 (0.14-0.57; <.001)	1.54 (1.12-2.11; .008)	0.64 (0.28-1.49; .30)	1.53 (0.83-2.83; .18)
Dose-intense regimens (n = 312)*	162	1.24 (0.82-1.88; .30)	0.90 (0.66-1.22; .49)	1.85 (0.87-3.93; .11)	0.76 (0.35-1.62; .47)
Less dose-intense regimens (n = 180)†	153	1.26 (0.77-2.06; .37)	1.75 (1.29-2.37; <.001)	0.14 (0.02-1.07; .06)	0.56 (0.22-1.41; .22)
Baseline CD4 count (cells/µL)‡
<50 (n = 175)	124	0.96 (0.80-1.16; .68)	1.04 (0.91-1.19; .53)	0.74 (0.57-0.97; .03)	0.96 (0.76-1.22; .75)
50-199 (n = 373)	217	0.97 (0.93-1.00; .08)	0.99 (0.96-1.02; .42)	1.00 (0.93-1.08; .93)	0.96 (0.91-1.01; .13)
≥200 (n = 829)	413	1.00 (1.00-1.00; .97)	1.00 (1.00-1.00; .68)	0.96 (0.92-0.99; .02)	1.00 (0.99-1.00; .14)

The model was adjusted for age, gender, history of AIDS, time of enrollment, type of lymphoma, and aaIPI.

Dose-intense regimens are intensive regimens and ACVBP.

Less dose-intense regimens are VS, low-dose or modified CHOP, and the Remick regimen.

Change in OR as per 10-unit increase of CD4 count.